Citations and Press Coverage

• Venture Capital in Latin America and the Caribbean

• SYNTHIA™ retrosynthesis software, powerful AI software accelerating drug discovery

• Impacts of the COVID-19 pandemic on EU industries

• Why small-molecule drug discovery is having a moment

• Breaking Through The Glass Ceiling - A Spring For Women In Artificial Intelligence

• The Future of Biopharma
• Intelligent Drug Discovery Powered by AI
• Ten Years on Measuring the Return from Pharmaceutical Innovation 2019
• Patient access to innovative medicines in Europe A collaborative and value-based approach

• Human Cells + Tech = Accelerated Drug Development and Treatment

• AI series (part IV): The race is on – using data to transform drug development

• Samsung BioLogics: A World Leader in Biopharmaceutical Manufacturing

• 50 Years of Global Health Progress

• The Promise of Targeted Innovation

• Sectoral Systems of Innovation and the UK’s Competitiveness: The UK Biopharmaceutical Sector

• Expanding the medicinal chemistry synthetic toolbox

• Supporting Client Projects for CDMO Success

• CRO Report Notes Issues With Clinical Applications
• The Asia-Pacific Region: A Hot Spot For Clinical Trials

• Harnessing the Power of AI Technology for Drug Discovery Treatments

• Keys to Implementing AI in Drug Discovery

• “In the next decade, Artificial Intelligence will be a cornerstone of the pharmaceutical and biotech sector”

• Partnerships to Accelerate AI Health Research

• Big Opportunities Remain in Small Molecule Innovation

• SUPPLY CHAIN VITAL SIGNS: 2022 Pharmaceutical Industry Study

• The Innovation Imperative: Pioneering New Modalities for Therapeutic Leadership

Reach our exclusive audience of biopharma and healthcare decision makers

At BiopharmaTrend, we dive deep into the most exciting areas of life sciences, from AI and digital health to neurotech and aging. Our content covers the latest in biotech innovations, clinical trials, and emerging startups, offering a comprehensive view of the future of healthcare. Partner with us to reach an engaged audience passionate about the cutting-edge developments shaping our bioeconomy and society.